5,000 Shares in GlaxoSmithKline PLC (GSK) Purchased by Waldron LP
Waldron LP bought a new position in shares of GlaxoSmithKline PLC (NYSE:GSK) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 5,000 shares of the pharmaceutical company’s stock, valued at approximately $203,000.
Several other institutional investors have also recently made changes to their positions in the stock. Keystone Financial Planning Inc. increased its position in shares of GlaxoSmithKline PLC by 1.7% during the 3rd quarter. Keystone Financial Planning Inc. now owns 133,216 shares of the pharmaceutical company’s stock worth $5,409,000 after purchasing an additional 2,210 shares in the last quarter. Spectrum Management Group Inc. acquired a new stake in shares of GlaxoSmithKline PLC during the 3rd quarter worth about $505,000. Ameriprise Financial Inc. increased its position in shares of GlaxoSmithKline PLC by 7.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,855,142 shares of the pharmaceutical company’s stock worth $75,028,000 after purchasing an additional 122,634 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of GlaxoSmithKline PLC during the 3rd quarter worth about $1,209,000. Finally, Advisors Asset Management Inc. increased its position in shares of GlaxoSmithKline PLC by 8.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 171,442 shares of the pharmaceutical company’s stock worth $6,961,000 after purchasing an additional 13,447 shares in the last quarter. Institutional investors and hedge funds own 9.32% of the company’s stock.
A number of equities research analysts recently issued reports on GSK shares. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Wednesday, October 18th. Argus reiterated a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. Investec cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $44.33.
Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down $0.13 during trading hours on Friday, hitting $35.06. 2,585,265 shares of the stock traded hands, compared to its average volume of 6,982,297. GlaxoSmithKline PLC has a 12 month low of $34.72 and a 12 month high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. The firm has a market cap of $86,224.50, a PE ratio of 12.43, a price-to-earnings-growth ratio of 1.94 and a beta of 1.00.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be given a dividend of $0.5037 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 annualized dividend and a dividend yield of 5.75%. GlaxoSmithKline PLC’s payout ratio is currently 163.12%.
In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.00% of the stock is owned by insiders.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.